Key result
Among patients with acute coronary syndromes or stroke, 19% exhibited high-on-aspirin platelet reactivity, with beta-blocker treatment significantly increasing the probability of responding to aspirin (OR 4.46).
Cross-Sectional (n=116)
Yes
Odds Ratio: 4.459 (95% CI 1.688–11.778)
Absolute Event Rate: 88.8% vs 63.9%
p-value: p=0.003
High-on-aspirin residual platelet reactivity is present in nearly one-fifth of patients with ACS or stroke and is associated with concomitant antibiotic therapy and higher LDL levels, while beta-blocker use and history of MI are associated with better aspirin response.
Beta-blocker association with better aspirin response in ACS/stroke is hypothesis-generating; prospective trials needed before clinical consideration.
Objective: The aim of this study was to evaluate the prevalence of aspirin non-responsiveness using whole blood multiple electrode aggregometry and to investigate the role of different clinical and laboratory variables associated with the lack of response. Methods: The present study included 116 aspirin treated patients presented with acute coronary syndromes or stroke. Response to aspirin was assessed by impedance aggregometry using arachidonic acid as agonist, in a final concentration of 0.5 mM (ASPI test). Results: In our data set 81% (n=94) were responders and 19% (n=22) non-responders showing high-on-aspirin platelet reactivity. Correlation analysis showed that the ward of admittance, low-density lipoproteins (LDL), concomitant antibiotic treatment, beta-adrenergic receptor blockers, history of myocardial infarction as well as PCI performed on Cardiology patients have different degrees of association with aspirin response. Conclusion: Concomitant treatment with beta-adrenergic receptor inhibitors, history of myocardial infarction and Cardiology ward admittance significantly increased the chance of responding to aspirin treatment whereas antibiotic therapy and low-density lipoproteins cholesterol seemed to increase the risk of high-on-aspirin residual platelet reactivity.
No takes yet. Share an insight, caveat, or question.
Mărginean et al. (2016) conducted a cross-sectional in Acute coronary syndromes or ischemic stroke (n=116). Beta-adrenergic receptor blockers vs. No beta-blocker treatment was evaluated on Aspirin responsiveness (AUC < 40 U) (OR 4.459, 95% CI 1.688-11.778, p=0.003). Among patients with acute coronary syndromes or stroke, 19% exhibited high-on-aspirin platelet reactivity, with beta-blocker treatment significantly increasing the probability of responding to aspirin (OR 4.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: